glp 1 and 2 agonist GLP-1 Receptor Services for Type Diabetes Obesity Drug Development GLP-1RAs Reduce External Eating Behavior
Description
The doses selected for Phase 3 (use our dosing calculator for personalized guidance), based on Phase 2 exposure-response analyses, were 6 mg, 12 mg, and 36 mg for obesity indications and 3 mg, 12 mg, and 36 mg for diabetes indications, reflecting a narrower and somewhat lower dose range than the Phase 2 program's maximum of 45 mg
[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Mann JFE, et al
Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Absorption Characteristics and the Food Effect The absence of a clinically meaningful food effect is one of orforglipron's most important practical advantages
Hippisley-Cox J, Young D, Coupland C, et al
In some trial data, lean mass loss has exceeded what clinicians expected at higher doses and faster weight loss rates
